Latest Conference Articles

A lower proportion of patients in the belimumab treatment group experienced ≥1 kidney flare compared with placebo in the overall population.

Stephen Ziegler, PhD, JD, discusses the challenges cannabis treatment presents as a form of complementary therapy for rheumatic disease.

Stephen Ziegler, PhD, JD, describes the various alternative and complementary treatments available for palliative care and pain management in patients with rheumatic disease.

Stephen Ziegler, PhD, JD, explains pain management and prescribing opioid medications in the wake of Ruan v United States.

Elizabeth Volkmann, MD, MS, explains the current treatment options available for SSc-ILD and how to evaluate and manage this patient population.

Elizabeth Volkmann, MD, MS, discusses systemic sclerosis associated interstitial lung disease and how to evaluate subclinical, clinical, and progressive disease for the best outcome.

Patients with IBD-RA and depression were younger, more likely to be female, and were more frequently White compared with controls.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Susan Goodman, MD, discusses pre and perioperative management of rheumatic disease.

The CASTLE-HTx trial provides insight into the effects of catheter ablation in patients with AFib and end-stage heart failure, with potentially practice-changing implications.

Data from a phase 1 trial in healthy adults indicates muvalaplin, an oral agent, could find a role in lowering Lp(a).

A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.

A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.

ORION-8 results showed the change in LDL-C from baseline in the 3-year open-label extension was similar to the change observed during 18 months of placebo-controlled comparison.

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

With BridgeBio Pharma Inc. expecting to complete a regulatory submission prior to the close of 2023, the 30-month results of ATTRibute-CM provide the most comprehensive overview yet of the benefit-risk profile for acoramidis in ATTR-CM.

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A study of more than 15,000 individuals suggests regular physical activity may help prevent the development of atrial fibrillation, as well as the incidence of stroke and MACE.

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

Presented at ASRS 2023, results from FARETINA-AMD suggest positive early treatment patterns and outcomes in patients with nAMD initiating faricimab treatment.